Navigation Links
Development of an adrenergic α2a receptor binding assay using the LEADseeker Multimodality Imaging System

Key words: α2c receptor GPCR receptor binding assay LEADseeker SPA Imaging Beads

The α2-adrenergic receptors are G protein-coupled receptors that play a key role in the control of numerous physiological functions such as renal Na+ re-absorption, insulin secretion, platelet aggregation, and neurotransmitter release at sympathetic nerve endings (1). They consist of three highly homologous subtypes encoded by distinct genes: α2a, α2b, and α2c. Both α2a and α2c subtypes are required for normal presynaptic control of neurotransmitter release from sympathetic nerves from the heart and from central noradrenergic neurons. α2a adrenergic receptors inhibit transmitter release at high stimulation frequencies whilst the α2c subtype modulates neurotransmission at lower levels of nerve activity (2). The α2c receptor is distinguishable from α2a and α2b receptors by its sensitivity to prazosin (3).

This application note describes a 384-well adrenergic α2c receptor binding assay developed using the LEADseeker™ Multimodality Imaging System.

Products used

LEADseeker Multimodality Imaging System 18-1140-71

Wheat Germ Agglutinin (WGA) YOx RPNQ0270
SPA Imaging Beads

[0-methyl-3H]Rauwolscine TRK685

Other materials required
Human recombinant adrenergic α2c receptor membrane preparation (Euroscr een, ES-032-M)

Prazosin hydrochloride (Sigma, P7791)

Rauwolscine hydrochloride (Sigma, R104)

Costar™ solid white 384-well microplate (Corning, 3705)

Buffer: 50-mM Tris pH 7.4
5-mM MgCl2
50-mM NaCl

GraphPad Prism™ software v4.0 (GraphPad Software)

Human recombinant α2c receptor membrane preparation was used in conjunction with [0-methyl-3H]Rauwolscine ligand and WGA YOx SPA Imaging Beads. Non-specific binding (NSB) was determined in the presence of 6-µM prazosin. The standard assay format was as follows:

1. Reagents were added in the following order: buffer, unlabeled ligand (NSB wells), labeled ligand, and precoupled bead and membrane. Total assay volume was 50 µl.

2. Diluted membrane and bead were precoupled for 30 min on a roller mixer at 2–8 ºC.

3. Wells contained 10 µl of 6.5-nM [0-methyl3H]Rauwolscine (final concentration 1.3 nM) unless otherwise stated. Wells also contained 5 µg of membrane and 250 µg of WGA YOx SPA Imaging Beads. Precoupled bead and membrane was added in a 20-µl volume.

4. NSB wells contained 10 µl of 30-µM prazosin (final concentration 6 µM) in addition to the above.

5. Plates were sealed and incubated in darkness for 3 h at room temperature (20–25 ºC) unless otherwise stated.

6. Following incubation, plates were imaged on the LEADseeker Multimodality Imaging System for 5 min using quasi-coincident averaging and 3 ×3 binning.

Kd determination
Saturation binding was performed with dilutions of [0-methyl-3H]Rauwolscine to give a range of concentrations from 0.07 to 8.8 nM in the wells. Plates were incubated for 5 h prior to imaging. Figure 1 shows the saturation curve, which was fitted using nonlinear regression with the data analysis software package GraphPad Prism v4.0. Over two experiments the mean Kd value was determined to be 1.3 nM (95% confidence intervals 0.8 to 1.9 nM), estimated directly from the curve. Figure 1 is representative of the data obtained.

DMSO tolerance
Dilutions of DMSO were prepared in assay buffer to give a range of concentrations from 0.25% (v/v) to 5% (v/v) in the well. The results shown in Figure 2 indicate the assay was tolerant to DMSO up to a final concentration of 1% (v/v).

IC50 determination
Competitive binding of 1.3-nM [0-methyl-3H]Rauwolscine with rauwolscine (Fig 3A) and prazosin (Fig 3B) was assessed and the IC50 value of each ligand calculated. Final concentrations in the wells were from 0.0004 to 4000 nM and 0.25 to 20000 nM respectively. DMSO was present at a final concentration of 1% v/v in each well.

Over two experiments, the mean rauwolscine IC50 value was determined to be 3.1 nM (95% confidence interval range 2.7–3.7 nM) and the mean Ki value was 1.6 nM (95% confidence intervals 1.3–1.8 nM). The mean prazosin IC50 value was determined to be 430 nM (95% confidence interval range 336–535 nM) and the mean Ki value was 215 nM (95% confidence intervals 168–267 nM).

Time course
A time course was performed using standard reagent concentrations detailed in the protocol with an increased incubation time of 17 h. The assay a ppeared to be stable for at least 17 h as demonstrated by the curve in Figure 4.

Z’ analysis
Finally, two independent Z’ analysis (4) evaluations were performed, each using 48 replicate values for "total" and NSB wells. DMSO was present at a final concentration of 1% (v/v) in each well. A mean Z’ value of 0.80 was generated. Figure 5 is representative of the data obtained. This is well within the acceptable Z’ value range (0.5–1.0) and confirmed the robustness of the assay.

The adrenergic α2c receptor binding assay has been successfully miniaturized to a 384-well format using the LEADseeker Multimodality Imaging System and is suitable for adaptation to automated screening formats. The assay is tolerant to DMSO up to a concentration of 1% (v/v), robust; achieving a mean Z’ value of 0.80, and has a stability window of at least 17 h.

1. Ruffolo, R. R. Jnr et al. Annual Review Pharmacological Toxicology 32, 243–279 (1993).

2. Hein, L. et al. Nature 402, 181–184 (1999).

3. Bylund, D.B. et al. Pharmacological Reviews 46, 121–136 (1994).

4. Zhang, J. et al. Journal Biomolecular Screening 4 (2), 67–73 (1999).

back to top


Page: All 1 2 3 4

Related biology technology :

1. The let-7 microRNA Family Regulates RAS: Implications for Development and Oncogenesis
2. Rapid Method Development With the BioLogic DuoFlow Chromatography System for the Purification of His-Tagged Proteins
3. A Multiple Mutation Model System as a Test Development and Training Tool for Denaturing Gradient Gel Electrophoresis
4. Development of a Multiplex Bead-Based Assay for Antibody Screening of a Nonhuman Primate Colony on the Bio-Plex System
5. Development of a histamine H1 receptor binding assay using the LEADseeker Multimodality Imaging System
6. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
7. Development of an NK2 neuropeptide receptor binding assay using LEADseeker Multimodality Imaging System
8. Development of a CRF1 neuropeptide receptor binding assay using LEADseeker Multimodality Imaging System
9. Development of Radioligand Binding Assays for the Motilin Receptor Using ScreenReady Targets.
10. Screening for potential beta 2-adrenergic receptor antagonists using CypHer5E and IN Cell Analyzer 1000
11. Screening for β2-adrenergic receptor agonists using the pH-sensitive dye,CypHer5, and the IN Cell Analyzer 3000
Post Your Comments:

(Date:1/21/2017)... 2017 Interpace Diagnostics Group, Inc. (NASDAQ: ... clinically useful molecular diagnostic tests and pathology services, ... securities purchase agreement with three  institutional investors to ... stock in a registered direct offering.  In a ... sell to the same investors warrants to purchase ...
(Date:1/21/2017)... , Jan. 20, 2017 Aratana Therapeutics, ... company focused on the licensing, development and commercialization of ... Pharm,s Best Company in North America ... the award based on the FDA approval ... (grapiprant tablets), ENTYCE ® (capromorelin oral solution) and ...
(Date:1/20/2017)... ... , ... The two newest companies to join the University City Science Center’s ... from The Wistar Institute, and Sanguis, launched by a trio of students from the ... Vironika is developing a treatment for a chronic viral infection and its associated diseases, ...
(Date:1/20/2017)... Ginkgo Bioworks, the organism company, announced ... the synthesis and assembly of DNA. The acquisition ... synthetic DNA into Ginkgo,s automated organism engineering foundries, ... of new organism designs for application across a ... founded to significantly increase the world,s capacity to ...
Breaking Biology Technology:
(Date:12/19/2016)... , 19 de diciembre de 2016  Mosaic Biomedicals SL ... desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera comenzar ... 2017, con múltiples sitios previstos a lo largo de Europa y ... MSC-1 es ... inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa en ...
(Date:12/15/2016)...   WaferGen Bio-systems, Inc. (NASDAQ: ... today that on December 13, 2016, it received a ... Stock Market LLC which acknowledged that, as of December ... stock had been at $1.00 or greater for ten ... Listing Rule 5550(a)(2) of the Nasdaq Stock Market. ...
(Date:12/12/2016)...  Researchers at Trinity College, Dublin, are opening ... the material with Silly Putty. The mixture (known as ... to sense pulse, blood pressure, respiration, and even ... The research team,s findings were published Thursday ... ...
Breaking Biology News(10 mins):